Abstract: An apparatus for treating myofascial and/or musculoskeletal tissue imbalances. The apparatus comprises a soft tissue mobilizing device having a front surface and a back surface. The back surface has an adhesive to adhere the device directly to the soft tissue area of a patient's body where muscle tension, aches and pain are present. The device when applied decompresses the soft tissue area being treated. The front surface includes a tab gripping mechanism to allow the patient or a therapist to grip the tab for manually lifting and shifting the soft tissue area under the mobilizing device being treated. The manual lifting and shifting of the patient's soft tissue reduces the time period for normalizing the myofascial and/or musculoskeletal tissue area being treated.

Abstract: Embodiments of the invention include a method and a device for increasing blood flow and controlling the temperature of a mammal by applying a desired pressure to extremities of a mammal. The device generally includes a pliant body element that is adapted to receive a portion of an extremity of the mammal therein, and then apply a pressure to a portion of the extremity when a pressure is provided to a region in which the extremity is positioned within the pliant body element. By evacuating the region in which the extremity is enclosed, a contact surface area between the extremity of a mammal and the pliant body element is increased, due to the external atmospheric pressure acting on the pliant body element against the skin of the extremity of the mammal. The application of pressure assures that sufficient contact and thermal heat transfer (heating or cooling) is provided to the extremity of the mammal.

Abstract: A personal massage device includes a front end and a back end, and may also include a third end. A curved shaft is enclosed in both the front end and the back end. A sliding component is placed on one end of the curved shaft. The design of the curved shaft and sliding component enables the front end to bend toward and away from the back end. If included, the third end can be attached to the back end. The device further includes a motor enclosed in each end. The motors in the front and third ends are adapted for creating vibration at various frequencies and amplitudes, while the motor in the back end rotates the curved shaft to generate the bending motion. To enhance the massaging effect of the device, the device is capable of simultaneously bending and vibrating, and simultaneously stimulating different areas of the body.

Abstract: A CPR apparatus includes a chest compression unit and mounting apparatus for mounting the chest compression unit on a patient. The chest compression unit includes a plunger disposed in a housing. At its one end extending from the housing the plunger has a compression member. The plunger is driven in a reciprocating manner by a reversible electromotor via a mechanical apparatus for translating rotational motion to linear motion or by a linear induction electromotor. The chest compression unit includes an electromotor control unit including a microprocessor, a first monitor for monitoring the position of the plunger in respect of the housing and a second monitor for monitoring the position of the plunger in respect of the mechanical apparatus for translating rotational motion to linear motion or the rotor of the linear induction electromotor. The monitored positions are communicated to the electromotor control unit. Also disclosed is a corresponding CPR method.

Abstract: A method for performing cardiopulmonary resuscitation (CPR) includes elevating the head, heart and shoulders of an individual from a starting elevation angle to a final elevation angle greater than zero degrees relative to horizontal while performing CPR by repeatedly compressing the chest. The method includes elevating the brain within a time period selected to be slow enough to permit a sufficient amount of blood to flow to the brain throughout the elevation time period. The method also includes regulating the intrathoracic pressure of the individual while performing CPR. The performance of chest compressions is stopped and after stopping the performance of chest compressions, the head, heart, and shoulders are promptly from the final elevation angle within a timeframe selected to prevent significant drainage of blood from the brain until the head, heart and shoulders are lowered.

Abstract: A wearable mobile terminal is provided that includes a base provided in an insole of a shoe, a pressure sensing unit provided in the base to sense a pressure selectively applied when a user walks, an acupressure unit provided to apply an acupressure to the user's foot, when the pressure is applied to the pressure sensing unit; and a wireless communication unit synchronized with an external mobile terminal.

Abstract: A sterile glass pharmaceutical container or vessel such as, but not limited to, vials for holding pharmaceutical products or vaccines in a hermetic and/or sterile state. The sterile glass pharmaceutical container undergoes a strengthening process that produces compression at the surface and tension within the container wall. The strengthening process is designed such that the tension within the wall is great enough to ensure catastrophic failure of the pharmaceutical container, thus rendering the product unusable, should sterility be compromised by a through-wall crack. The tension is greater than a threshold central tension, above which catastrophic failure of the pharmaceutical container is guaranteed, thus eliminating any potential for violation of pharmaceutical integrity or sterility (such as stable cracks) in the glass packaging which are not easily identifiable in an otherwise seemingly intact pharmaceutical container.

Abstract: A laminate film includes a substrate layer; and a metal oxide layer which is provided on one surface or both surfaces of the substrate layer and contains a metal oxide. Further, the oxygen permeability measured under defined conditions is 20 ml/m2·day·MPa or less and the water vapor permeability measured under conditions of a temperature of 40° C. and a humidity of 90% RH is 2.5 g/m2·day or greater. In addition, when the K? beam intensity of a metal constituting the metal oxide which is obtained by performing fluorescence X-ray analysis on the metal oxide layer is set to A and the K? beam intensity of the metal which is obtained by performing fluorescence X-ray analysis on a metal layer formed of the metal constituting the metal oxide is set to B, A/B is equal to or greater than 0.20 and equal to or less than 0.97.

Abstract: A syringe holding assembly for filling a syringe with medication includes a block that has a first well therein to insertably receive a medication bottle. The block has a second well therein to insertably receive a syringe. The first well is aligned with the second well to align the syringe with the medication bottle. In this way a user with limited hand dexterity is assisted to fill the syringe with medication. An adapter is provided to receive a vial. The adapter is removably positioned in the first well thereby facilitating the vial to be aligned with the syringe.

Abstract: The programmable medicine dispenser is a secured pill dispenser. The programmable medicine dispenser is a locked dispenser that: 1) dispenses a controlled medical substance at the single dose level; and 2) controls access to the contents of the locked dispenser. The programmable medicine dispenser: 1) dispenses the controlled medical substance in single dose quantities; 2) dispenses a single dose of the controlled medical substance at regular intervals; 3) verifies the physical presence of a patient before releasing the single dose of the controlled medical substance; 4) notifies the appropriate authority that a single dose has been dispensed; 5) limits access to the hopper of programmable medicine dispenser to a pharmacy or other secured location; and, 6) operates a beacon to locate the programmable medicine dispenser. The programmable medicine dispenser comprises a dispenser and a control system. The control system is stored within and controls access to the dispenser.

Abstract: A portable compact scaled-down programmable system for authorized dispensing of medicines is illustrated. The system includes at least one enclosure, a dispenser unit having an integrated cap and a plurality of dispensing slots, adapted to facilitate dispense of at least one medicine to an authentic user. The system further includes a driving mechanism for the upward and downward movement of the dispenser unit, a control unit to facilitate controlled functioning of functional units of the system, a primary sensor unit to facilitate the identification and authorization, a power supply unit, a micro-USB, a GNSS module, a set of status indicators having a liquid crystal display, a speaker, a vibrator and a LED, a set of knobs, and a communication facilitator. Further, the system can be operated either in stand-alone mode and or in paired mode. The system is configured to include a plurality of internet of things [IoT] modules.

Abstract: A medicine bottle timer lid. The medicine bottle timer lid includes a housing removably securable to a medicine bottle having a display operably connected to a timer. The housing further includes a battery and a sensor disposed therein. The sensor is configured to detect the position of the housing with respect to the medicine bottle. The timer is configured to begin counting when the housing is secured to the medicine bottle, and the display shows the amount of time that has elapsed since the housing was secured to the medicine bottle. The timer is further configured to reset upon removal of the housing from the medicine bottle. The medicine bottle timer lid allows individuals to automatically keep track of their medication.

Abstract: A system comprising a nasogastric tube comprising a nasogastric location element, a feeding mechanism, a suction mechanism configured to sealingly draw an inner wall of an esophagus against said nasogastric tube, and a gastric decompression mechanism.

Abstract: The invention relates to a PEG probe having a PEG tube, an outer holding plate, through which the PEG tube is fed and in which the PEG tube is fastened, and a funnel adapter, which is associated with an outer end region of the PEG tube. A tightly closing valve is arranged either in the PEG tube between the outer holding plate and the outer end region or on the outer end region of the PEG tube. The valve blocks the flow through the PEG tube in a closed position and allows said flow at least in the full cross-section of the PEG tube in an open position. The valve has a valve body and a valve housing. The valve body is connected to and movable by means of a handle accessible from outside. The valve body is supported in the valve housing.

Abstract: Described herein are three-dimensional (3D) culture systems that can be used to produce enamel organoids that generate enamel products. The invention features methods of culturing a variety of cell types to produce such enamel organoids; the organoids themselves; enamel products generated by the organoids; and methods of fashioning the enamel products into surgical restorations, including dental restorations and other prostheses.

Abstract: The object of the present invention is to provide a composition for a laminated coating film having designability to a coated body and weather resistance. The present invention provides a composition for a laminated coating film, comprising silicon oxide-coated iron oxide particles, wherein at least a part of the surface of said iron oxide particles is coated with silicon oxide, wherein the diameter of said iron oxide particles is 1 to 50 nm, and wherein the average reflectivity of said silicon oxide-coated iron oxide particles for the light of the wavelengths of 620 to 750 nm is 25% or less. It is preferable that the transmittance of the dispersion comprising said silicon oxide-coated iron oxide particles for the light of the wavelength of 200 to 420 nm is 2.0% or less, and the transmittance of the same for the light of the wavelength of 620 to 780 nm is 80% or more.

Abstract: Anhydrous antiperspirant composition in aerosol form comprising an antiperspirant active agent and a water-insoluble film-forming block ethylenic polymer The present invention relates to an anhydrous composition in aerosol form containing: i) an oily phase comprising, in a physiologically acceptable medium: —at least one volatile oil, and —one or more antiperspirant active agents chosen from aluminum and/or zirconium salts, and —one or more water-insoluble film-forming block ethylenic polymers comprising a first block with a glass transition temperature (Tg) of greater than or equal to 85° C. and a second block with a Tg of less than or equal to 20° C., and ii) one or more propellants; the said oily phase containing less than 15% by weight and even more preferably less than 12% by weight of non-volatile polydimethylsiloxane relative to the total weight of the oils.

Abstract: Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.

Abstract: A soluble zinc polyphosphate complex made by combining ingredients which include an organic zinc salt and a plurality of long chain polyphosphates having 6 or more phosphate polymer units, the organic zinc salt and long chain polyphosphates being mixed in amounts that provide a phosphorus to zinc mole ratio of 15:1 to about 55:1. Further provided is a method of making this soluble zinc polyphosphate.

Abstract: Disclosed in the present specification are: a skin whitening composition having a skin whitening effect by controlling the secretion of exosomes to be secreted from melanocytes; and a method for screening for materials having a skin whitening effect. The skin whitening composition can promote apoptosis of melanocytes by inhibiting the amount of secretion of exosomes to be secreted from melanocytes, and consequently inhibits the generation of melanin through the apoptosis of melanocytes, thereby exhibiting a skin whitening effect.

Abstract: Topical compositions comprising a retinoid, a low irritation polymeric cleansing agent and a cosmetically-acceptable topical carrier are provided. Such compositions provide improved retinoid activity for treating for example signs of skin aging, acne, or rosacea.

Abstract: A cosmetic composition for the temporary shaping of keratinic fibers, containing: at least one non-crosslinked, hydrophobically modified (meth)acrylic acid copolymer at least one crosslinked, hydrophobically modified (meth)acrylic acid copolymer, its use and method using such a composition.

Abstract: Provided are skin care compositions that are useful as SPF and UV absorption boosters in formulations containing inorganic metal oxides. The compositions comprise (a) 0.1 to 20 weight % inorganic metal oxide particles, based on the weight of the composition, (b) 0.1 to 15 weight % copolymer particles dispersed in an aqueous medium, wherein the copolymer particles comprise polymerized units derived from (i) 0.1 to 20 weight % of phosphorus acid monomers, and (ii) 80 to 99.9 weight % of comonomers, (c) 0.1 to 35 weight % silicone fluid, based on the total weight of the composition, and (d) a dermatologically acceptable carrier. Also provided are methods of protecting skin from UVA and UVB damage comprising topically administering such compositions to the skin, and methods of boosting the SPF or UV absorption of a sunscreen composition containing inorganic metal oxide particles comprising including such copolymer particles in the composition.

Abstract: Disclosed are a fermented ginseng berry Pleurotus ferulae product and a cosmetic composition containing the same. The fermented ginseng berry Pleurotus ferulae product is useful for anti-oxidation, anti-inflammation, collagen synthesis facilitation, skin wrinkle care, whitening, moisturizing, skin barrier improvement and atopy alleviation.

Abstract: The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 ?m, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.

Abstract: Methods of inhibiting the growth of cells or inducing cell death by contacting the cells with or introducing into the cells a composition including a 5? triphosphate, 2? fluoro-modified pyrimidine non-linear single stranded RNA at least 17 nucleotides long with a least 3 base pairings or a 5? triphosphate, 2? fluoro-modified double stranded RNA at least 17 base pairs long in an amount effective to inhibit cell growth, induce cell death or induce cytokine production by the cells. The methods also include administration of the compositions to a subject. The subject may have a proliferative disorder or infectious disease and administration of the compositions provided herein may treat the disorder or disease.

Abstract: An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods.

Abstract: The present technology provides intravaginal devices designed to deliver lubricants to the vagina for a sustained period of time. The intravaginal devices include a first segment comprising an outer surface and a lumen containing a lubricant, wherein the first segment is configured to deliver the contents of the lumen to the outer surface, and the first segment comprises a polymer selected from the group consisting of a hydrophilic, semi-permeable elastomer and a hydrophobic elastomer. The lubricant may be an aqueous lubricant. The present technology further provides an intravaginal device including a solid first segment that includes a hydrophilic semi-permeable elastomer, an outer surface and an aqueous lubricant, wherein the first segment is configured to deliver the aqueous lubricant to the outer surface.

Abstract: The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.

Abstract: This invention provides compositions comprising a byetta, fish oil, and a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral or rectal administration of a byetta.

Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Abstract: A process for preparing a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and, optionally, an inhaled corticosteroid, is provided.

Abstract: The present disclosure provides methods and systems for forming stable droplets as part of an emulsion. The emulsion may be, for example, formed by bringing an aqueous phase in contact with an oil phase at a droplet generation junction of a droplet generator. Droplets of the present disclosure may be used for holding compositions for various uses.

Abstract: A substantially surface active agent-free and substantially polymeric agent-free foamable composition is disclosed, which includes short-chain alcohol, water, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. Also disclosed is a method of treatment by applying the substantially surface active agent-free and substantially polymeric agent-free foamable composition.

Abstract: Provided herein are methods and compositions for the targeted delivery to myometrial tissue of one or more agents capable of regulating contractility of myometrial tissue, wherein the one or more agents are contained or encapsulated within a polymeric delivery vehicle conjugated with one or more molecules that recognizes and/or is capable of binding, directly or indirectly, to the oxytocin receptor.

Abstract: Dermal delivery compositions are provided. Aspects of the dermal delivery compositions include the presence of active agent-calcium phosphate particle complexes, where these complexes include uniform, rigid, spherical nanoporous calcium phosphate particles associated with one or more active agents. Also provided are methods of using the compositions in active agent delivery applications.

Abstract: Therapeutic compositions are disclosed which contain a therapeutic agent and a bile acid or bile acid conjugate. The compositions can be absorbed via enterohepatic circulation. The compositions include a cationic moiety and an anionic polymer, which are coupled through electrostatic interactions. The therapeutic compositions can be used for the treatment of diseases or disorders.

Abstract: Provided is a solid preparation showing improved stability of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea and a salt thereof in the solid preparation, and a method of stabilizing the compound in a solid preparation. A tablet containing not less than 25 mass % of the compound; a solid preparation containing (1) the compound, and (2) a fat and oil-like substance having a low melting point, which is selected from polyethylene glycol, glycerol monostearate and triethyl citrate; a method of stabilizing the compound in a tablet, including adding not less than 25 mass % of the compound; and a method of stabilizing the compound, including adding a fat and oil-like substance having a low melting point, which is selected from polyethylene glycol, glycerol monostearate and triethyl citrate to a solid preparation containing the compound.

Abstract: Provided herein is a celecoxib and amlodipine composition and method of making the same. The composition contains granules containing celecoxib. The amlodipine is incorporated into the composition as an extragranulate.

Abstract: A porous hollow silica particle with an interpolymer complex immobilized thereon is provided. The interpolymer complex comprises a first polymer immobilized to a surface of the silica particle, and a second polymer complexed with the first polymer. Pharmaceutical compositions comprising the silica particle, and methods of forming the silica particle are also provided.

Abstract: Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.

Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

Abstract: The invention relates to a monopolymer multifunctional sequenced cast polyurethane matrix produced simply and efficiently, by sequentially pouring various isocyanate/polyol complex phase solutions successively into a mold with alternating solidification of said phase solutions according to a defined order and respecting the polymerization stage (after the pot life and before the demolding time) of the sequence preceding the one being cast, so as to end with the casting of the last phase solution that will go up to the demolding time thereof and thereby finish the polymerization of the whole of the matrix. It is loaded, in its “reservoir” sequences, with naturally originating or synthesized transdermally penetrating or volatile active substances. They are medicating and therapeutic, cosmetic, phytosanitary or wellness substances, repellents, attractants, pheromones, biocides, perfumes or deodorants.

Abstract: The invention relates to a new use of diphenyleneiodonium (DPI) as an active substance against parasites of the family Trypanosomatidae, in particular against parasites of the genus Leishmania and Trypanosoma.

Abstract: Synthetically-derived S,S-heterodisubstituted disulfides that exhibit potent in vitro antibacterial activity against a variety of bacteria, including Staphylococcus aureus, methicillin-resistant Staphylococcus aureus and Francisella tularensis. The present invention provides compounds, methods and compositions effective to treat microbial/bacterial infections, and, especially, infections arising from bacteria which have developed resistance to conventional antibiotics.

Abstract: Disclosed herein is a method of prevention of progression of a multiple sclerosis in a patient, comprising the administration of methylglyoxal bis(guanylhydrazone) (MGBG) to the patient in need thereof. Also disclosed herein is a method of prevention or reduction in severity of the initiation phase of autoimmune response in a patient having multiple sclerosis, comprising the administration of MGBG to the patient in need thereof.

Abstract: The object of the present invention is the combination of palmitoylethanolamide (PEA) and lycopene, and/or pharmaceutically acceptable salts and/or derivatives thereof, the pharmaceutical formulations comprising the combination of PEA and lycopene, and/or pharmaceutically acceptable salts or derivatives thereof, optionally together with at least one pharmacologically acceptable excipient, and the use of the combination of PEA and lycopene, and/or pharmaceutically acceptable salts or derivatives thereof, and of the formulations comprising such a combination, in the treatment of inflammatory diseases.

Abstract: Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide pain relief when applied to a skin surface proximate a pain site.

Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.

Abstract: The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of micturitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.